These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Neuromyelitis optica spectrum disorders with antibodies to myelin oligodendrocyte glycoprotein or aquaporin-4: Clinical and paraclinical characteristics in Algerian patients. Bouzar M; Daoudi S; Hattab S; Bouzar AA; Deiva K; Wildemann B; Reindl M; Jarius S J Neurol Sci; 2017 Oct; 381():240-244. PubMed ID: 28991690 [TBL] [Abstract][Full Text] [Related]
3. Recurrent optic neuritis - Different patterns in multiple sclerosis, neuromyelitis optica spectrum disorders and MOG-antibody disease. Lotan I; Hellmann MA; Benninger F; Stiebel-Kalish H; Steiner I J Neuroimmunol; 2018 Nov; 324():115-118. PubMed ID: 30267996 [TBL] [Abstract][Full Text] [Related]
4. Radiological characteristics of myelin oligodendrocyte glycoprotein antibody disease. Salama S; Khan M; Levy M; Izbudak I Mult Scler Relat Disord; 2019 Apr; 29():15-22. PubMed ID: 30658259 [TBL] [Abstract][Full Text] [Related]
5. MOG antibody disease: A review of MOG antibody seropositive neuromyelitis optica spectrum disorder. Narayan R; Simpson A; Fritsche K; Salama S; Pardo S; Mealy M; Paul F; Levy M Mult Scler Relat Disord; 2018 Oct; 25():66-72. PubMed ID: 30048919 [TBL] [Abstract][Full Text] [Related]
6. Centrally-located transverse myelitis would facilitate the differentiation of NMOSD and MOG-AD from MS. Etemadifar M; Salari M; Etemadifar MR; Sabeti F; Fateh ST; Aminzade Z Mult Scler Relat Disord; 2022 Apr; 60():103664. PubMed ID: 35219242 [TBL] [Abstract][Full Text] [Related]
7. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. Jarius S; Ruprecht K; Kleiter I; Borisow N; Asgari N; Pitarokoili K; Pache F; Stich O; Beume LA; Hümmert MW; Ringelstein M; Trebst C; Winkelmann A; Schwarz A; Buttmann M; Zimmermann H; Kuchling J; Franciotta D; Capobianco M; Siebert E; Lukas C; Korporal-Kuhnke M; Haas J; Fechner K; Brandt AU; Schanda K; Aktas O; Paul F; Reindl M; Wildemann B; J Neuroinflammation; 2016 Sep; 13(1):280. PubMed ID: 27793206 [TBL] [Abstract][Full Text] [Related]
8. Brain and spinal cord lesion criteria distinguishes AQP4-positive neuromyelitis optica and MOG-positive disease from multiple sclerosis. Bensi C; Marrodan M; González A; Chertcoff A; Osa Sanz E; Chaves H; Schteinschnaider A; Correale J; Farez MF Mult Scler Relat Disord; 2018 Oct; 25():246-250. PubMed ID: 30144694 [TBL] [Abstract][Full Text] [Related]
9. Clinical and radiologic approach to 'typical' versus antibody-related optic neuritis. Caron-Cantin M; Cestari DM; Fortin E Curr Opin Ophthalmol; 2019 Nov; 30(6):412-417. PubMed ID: 31503075 [TBL] [Abstract][Full Text] [Related]
10. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin. Jarius S; Ruprecht K; Kleiter I; Borisow N; Asgari N; Pitarokoili K; Pache F; Stich O; Beume LA; Hümmert MW; Trebst C; Ringelstein M; Aktas O; Winkelmann A; Buttmann M; Schwarz A; Zimmermann H; Brandt AU; Franciotta D; Capobianco M; Kuchling J; Haas J; Korporal-Kuhnke M; Lillevang ST; Fechner K; Schanda K; Paul F; Wildemann B; Reindl M; J Neuroinflammation; 2016 Sep; 13(1):279. PubMed ID: 27788675 [TBL] [Abstract][Full Text] [Related]
11. Myelin-oligodendrocyte-glycoprotein (MOG) autoantibodies as potential markers of severe optic neuritis and subclinical retinal axonal degeneration. Havla J; Kümpfel T; Schinner R; Spadaro M; Schuh E; Meinl E; Hohlfeld R; Outteryck O J Neurol; 2017 Jan; 264(1):139-151. PubMed ID: 27844165 [TBL] [Abstract][Full Text] [Related]